Improving quality of life for millions of people with chronic pain

FDA Grants Breakthrough Device Designation to Remedee Labs for the management of Fibromyalgia

The FDA’s Breakthrough Device program exists to accelerate market access for devices that improve care for people with severely debilitating conditions. This designation recognizes both the highly innovative nature of Remedee’s device and its potential benefits for fibromyalgia patients adjunctively with standard of care. Obtaining Breakthrough Device status is a strong first step toward US market authorization.

Remedee Labs joins Future4care, the digital health startup accelerator.

Remedee Labs is the first startup to join Future4care, a digital health startup accelerator founded by Sanofi, Capgemini, Generali, and Orange to enable rapid development of e-health solutions.

Effectiveness clinical trials started

• Inclusion of the first patients in the Epikarthrose protocol for arthritis pain management
• Inclusion of the first patients in the Mistic protocol for Migraine pain management
• Fibrepik protocol submission for Fibromyalgia pain management

Partnership with the Foundation Rothschild Hospital

Launch of a clinical study aimed at proving milimeter waves therapy effects on migraines.

Remedee Labs joins 2 major international healthcare networks:

• Medtech Innovator: Based in Los Angeles, CA, Medtech Innovator became this year the world’s largest Accelerator for medical device companies. Remedee Labs was selected among 1000+ applicants to join the Accelerator program in 2020.
• JLABS by Johnson & Johnson Innovation: JLABS is a network of science incubators & coworking lab which enables innovators to accelerate the delivery of healthcare solutions to patients around the world.

Effectiveness clinical trials started

• Inclusion of the first patients in the Epikard protocol for pain management following heart surgery
• Epikarthrose protocol submission for arthritis pain management

Pre-Series A financing completed

Bringing the total funding to $12 million and allowing Remedee Labs to start effectiveness clinical trials.

ISO 13485 certification obtained

In 2019 Remedee Labs receives ISO 13485:2016 certification for its medical-device quality management system, underpinning the company’s commitment to quality and standards.

Remedee Labs’ first complete personal endorphin stimulation device delivered.

The wearable-format device is the first implementation of the MEET module, allowing the company to start clinical testing of its personal healthcare solution.

First clinical trial of our millimeter wave solution

Clinical validation of millimeter wave treatment innocuity.

MEET module patented by Remedee Labs

Remedee Labs develops its patented technology of a millimeter wave emitting module for medical usage.

Remedee Labs is created

Remedee Labs is founded in December 2016 with support from French technology research center CEA in Grenoble.

First integration of millimeter wave system into a small-form-factor, cost-effective device

Leading French technology research center CEA-LETI develops the first silicon chip, making millimeter wave frequencies accessible for consumer devices.

Research by the medical services of the French Department of Defense

While researching emerging defense technologies, a medical research team at the French Department of Defense reproduces the analgesic effect of millimeter waves and confirms the link between this effect and endorphins.

First treatment of pain using millimeter waves

Hospitals in Eastern Europe treated pain of over 3 million patients using millimeter wave medical equipment and validate its clinical viability.
Access to simpler and less costly analgesic medication subsequently leads to its abandon.